HBIO — Harvard Bioscience Income Statement
0.000.00%
Last trade - 00:00- $15.37m
- $48.22m
- $94.14m
Annual income statement for Harvard Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 102 | 119 | 113 | 112 | 94.1 |
| Cost of Revenue | |||||
| Gross Profit | 58 | 67.7 | 62.3 | 66.4 | 54.8 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 104 | 117 | 120 | 110 | 100 |
| Operating Profit | -1.66 | 2.07 | -6.93 | 1.89 | -6.21 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -7.29 | -0.14 | -9.18 | -2.56 | -11.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.81 | -0.288 | -9.52 | -3.42 | -12.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.81 | -0.288 | -9.52 | -3.42 | -12.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.81 | -0.288 | -9.52 | -3.42 | -12.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.136 | 0.013 | -0.196 | -0.075 | -0.272 |